Conceptos Categóricos

IMPORTANCIA DEL SEXO PARA LA ADMINISTRACION ADECUADA DE ANTIPSICOTICOS

IMPORTANCIA DEL SEXO PARA LA ADMINISTRACION ADECUADA DE ANTIPSICOTICOS

(especial para SIIC © Derechos reservados)
La mejoría del tratamiento de las mujeres con psicosis provendrá de la efectividad específica para el sexo y de la ausencia de efectos adversos indeseados.
seeman9.jpg Autor:
Mary V. Seeman
Columnista Experto de SIIC
Artículos publicados por Mary V. Seeman
Recepción del artículo
23 de Junio, 2006
Aprobación
29 de Junio, 2006
Primera edición
26 de Octubre, 2006
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
El propósito del presente artículo es ampliar los hallazgos publicados en un trabajo previo sobre las diferencias en la prescripción adecuada de antipsicóticos según el sexo del paciente. Esto se llevará a cabo mediante la evaluación de hallazgos nuevos sobre la relación médico-paciente, composición corporal femenina y masculina, estilo de vida y administración de medicación concomitante, ciclos hormonales, absorción y eliminación, metabolismo, unión a proteínas, flujo sanguíneo cerebral, función de los receptores y problemas característicos de las mujeres. Al tratar a las mujeres de acuerdo con las recomendaciones establecidas para los hombres, el riesgo de efectos adversos aumenta.

Palabras clave
Mujeres, diferencias sexuales, psicosis, antipsicóticos, efectos adversos, efectividad


Artículo completo

(castellano)
Extensión:  +/-8.05 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
The aim of this paper is to extend the findings of a previous article on sex differences in the optimal prescription of antipsychotic medications by examining new findings in the areas of the patient-doctor relationship, the body composition of women and men, life style and co-medication issues, hormonal cycles, absorption and elimination, metabolism, protein binding, brain blood flow, receptor functions, and problems specific to women. By treating women according to guidelines established for men, clinicians increase the risks of adverse effects in women.

Key words
Women, sex-differences, psychosis, antipsychotics, side-effects, effectiveness


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Salud Mental
Relacionadas: Farmacología, Medicina Farmacéutica, Medicina Interna, Obstetricia y Ginecología



Comprar este artículo
Extensión: 8.05 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Mary V. Seeman, Centre for Addiction and Mental Health, University of Toronto, M5T 1R8, 250 College St., Toronto, Canadá
Bibliografía del artículo
1. Miller MA. Gender-based differences in the toxicity of pharmaceuticals -the Food and Drug Administration's perspective. Int J Toxicol 2001; 20:149-152.
2. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2:349-51.
3. Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity .J Endocrinol 2003; 176:293-304.
4. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161:1324-33.
5. Tabenkin H, Goodwin MA, Zyzanski SJ, Stange KC, Medalie JH. Gender differences in time spent during direct observation of doctor-patient encounters. J Womens Health (Larchmt) 2004; 13:341-9.
6. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 1994; 51:826-36.
7. Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000; 61:344-8.
8. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003; 64 Suppl 16:10-13.
9. Ciccone GK, Holdcroft A. Drugs and sex differences: a review of drugs relating to anaesthesia. Br J Anaesthesia 1999; 82:255-65.
10. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause-related changes in body fat distribution. Ann N Y Acad Sci 2000; 904:502-6.
11. Derenne JL, Baldessarini RJ. Clozapine toxicity associated with smoking cessation: case report. Am J Ther 2005; 12:469-71.
12. MacIntosh H, Coleman T. Characteristics and prevalence of hardcore smokers attending UK general practitioners. BMC Fam Pract 2006; 29:7-24.
13. Zilberman M, Tavares H, El-Guebaly N. Gender similarities and differences: the prevalence and course of alcohol- and other substance-related disorders. J Addict Dis 2003; 22:61-74.
14. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23:119-27.
15. Cole TJ, Henry CJ. The Oxford Brookes basal metabolic rate database - a reanalysis. Public Health Nutr 2005; 8(7A):1202-12.
16. Daumit GL, Goldberg RW, Anthony C, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis 2005; 193:641-6.
17. Susce MT, Villanueva N, Díaz FJ, De León J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 2005; 66:167-73.
18. Meibohm B, Beierle I, Dedernforf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41:329-42.
19. Chetty M, Miller R. Oral contraceptives increase the plasma concentrations of chlorpromazine. Ther Drug Monit 2001; 23:556-8.
20. Dluzen DE. Unconventional effects of estrogen uncovered. Trends Pharmacol Sci 2005; 26:485-7.
21. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42:107-21.
22. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199:193-209.
23. Davis M. Gender differences in p-glycoprotein: drug toxicity and response. J Clin Oncol 2005; 23:6439-40.
24. Thurmann PA. Gender-related differences in pharmacokinetics and pharmacodynamics. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005; 48:536-40.
25. Vinge E. Men and women respond differently to drugs. Hormone-dependent pharmacodynamic differences are rarely studied. Lakartidningen 1998; 95:3177-82.
26. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64:2291-314.
27. David SR, Taylor CC, Kinon BJ, Breier A.The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22:1085-96.
28. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64:761-6.
29. Sweeney C, Blair CK, Anderson KE, Lazovich D, Folsom AR. Risk factors for breast cancer in elderly women. Am J Epidemiol 2004; 160:868-75.
30. Lalonde FM, Myslobodsky M. Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson's disease. Breast 2003; 12:280-2.
31. Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59:1147-54.
32. Harvey PW. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J Appl Toxicol 2005; 25:179-83.
33. Yamazawa K, Matsui H, Seki K, Sekiya S. A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women. Oncology 2003; 64:116-23.
34. Anthony M. Male/female differences in pharmacology: safety issues with QT-prolonging drugs. J Womens Health (Larchmt) 2005; 14:47-52.
35. Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006; 21:81-5.
36. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49 Suppl 1:15S-20S.
37. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999; 40:101-4.
38. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 2001; 21:14-20.
39. Rao ML, Hiemke C, Grasmader K, Baumann P; TDM Arbeitsgruppe Der AGNP. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr 2001; 69:510-7.
40. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25:46-53.
41. Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25:570-4.
42. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999; 60:36-40.
43. Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 2005; 19:395-401.
44. Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2004; 14:245-50.
45. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005; 14:19-29.
46. Blehar MC. Public health context of women's mental health research. Psychiatr Clin North Am 2003; 26:781-99.
47. Hofer A, Baumgartner S, Edlinger M, et al. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry 2005; 20:386-94.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
-->